These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 7585208)

  • 21. Investigations using photo affinity labeled analogues confirm the binding between sCD4 and the PND of HIV-1, MN.
    Dettin M; Scarinci C; Seraglia R; Di Bello C
    Biochem Biophys Res Commun; 1997 Dec; 241(2):584-8. PubMed ID: 9425315
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cytolysis by CCR5-using human immunodeficiency virus type 1 envelope glycoproteins is dependent on membrane fusion and can be inhibited by high levels of CD4 expression.
    LaBonte JA; Madani N; Sodroski J
    J Virol; 2003 Jun; 77(12):6645-59. PubMed ID: 12767984
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 95- and 25-kDa fragments of the human immunodeficiency virus envelope glycoprotein gp120 bind to the CD4 receptor.
    Nygren A; Bergman T; Matthews T; Jörnvall H; Wigzell H
    Proc Natl Acad Sci U S A; 1988 Sep; 85(17):6543-6. PubMed ID: 2842778
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A functional, discontinuous HIV-1 gp120 C3/C4 domain-derived, branched, synthetic peptide that binds to CD4 and inhibits MIP-1alpha chemokine binding.
    Howie SE; Fernandes ML; Heslop I; Hewson TJ; Cotton GJ; Moore MJ; Innes D; Ramage R; Harrison DJ
    FASEB J; 1999 Mar; 13(3):503-11. PubMed ID: 10064617
    [TBL] [Abstract][Full Text] [Related]  

  • 25. SPC3, a synthetic peptide derived from the V3 domain of human immunodeficiency virus type 1 (HIV-1) gp120, inhibits HIV-1 entry into CD4+ and CD4- cells by two distinct mechanisms.
    Yahi N; Fantini J; Baghdiguian S; Mabrouk K; Tamalet C; Rochat H; Van Rietschoten J; Sabatier JM
    Proc Natl Acad Sci U S A; 1995 May; 92(11):4867-71. PubMed ID: 7761414
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adenosine deaminase binding to human CD26 is inhibited by HIV-1 envelope glycoprotein gp120 and viral particles.
    Valenzuela A; Blanco J; Callebaut C; Jacotot E; Lluis C; Hovanessian AG; Franco R
    J Immunol; 1997 Apr; 158(8):3721-9. PubMed ID: 9103436
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of CD4 and major histocompatibility complex functional peptide sites and their homology with oligopeptides from human immunodeficiency virus type 1 glycoprotein gp120: role in AIDS pathogenesis.
    Zagury JF; Bernard J; Achour A; Astgen A; Lachgar A; Fall L; Carelli C; Issing W; Mbika JP; Picard O
    Proc Natl Acad Sci U S A; 1993 Aug; 90(16):7573-7. PubMed ID: 8356059
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A soluble recombinant polypeptide comprising the amino-terminal half of the extracellular region of the CD4 molecule contains an active binding site for human immunodeficiency virus.
    Berger EA; Fuerst TR; Moss B
    Proc Natl Acad Sci U S A; 1988 Apr; 85(7):2357-61. PubMed ID: 2451247
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HLA-DR is involved in the HIV-1 binding site on cells expressing MHC class II antigens.
    Mann DL; Read-Connole E; Arthur LO; Robey WG; Wernet P; Schneider EM; Blattner WA; Popovic M
    J Immunol; 1988 Aug; 141(4):1131-6. PubMed ID: 2840463
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The MHC-binding and gp120-binding functions of CD4 are separable.
    Lamarre D; Ashkenazi A; Fleury S; Smith DH; Sekaly RP; Capon DJ
    Science; 1989 Aug; 245(4919):743-6. PubMed ID: 2549633
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Structural studies on synthetic peptides from the principal neutralizing domain of HIV-1 gp120 that bind to CD4 and enhance HIV-1 infection.
    Dettin M; De Rossi A; Autiero M; Guardiola J; Chieco-Bianchi L; Di Bello C
    Biochem Biophys Res Commun; 1993 Mar; 191(2):364-70. PubMed ID: 8460995
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CD26 as a positive regulator of HIV envelope-glycoprotein induced apoptosis in CD4+ T cells.
    Jacotot E; Callebaut C; Blanco J; Rivière Y; Krust B; Hovanessian AG
    Adv Exp Med Biol; 1997; 421():207-16. PubMed ID: 9330699
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Revealing HIV's T cell passkey.
    Balter M
    Science; 1998 Jun; 280(5371):1833-4. PubMed ID: 9669932
    [No Abstract]   [Full Text] [Related]  

  • 34. Range of CD4-Bound Conformations of HIV-1 gp120, as Defined Using Conditional CD4-Induced Antibodies.
    Kaplan G; Roitburd-Berman A; Lewis GK; Gershoni JM
    J Virol; 2016 May; 90(9):4481-4493. PubMed ID: 26889042
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification of a phosphodiester hexanucleotide that inhibits HIV-1 infection in vitro on covalent linkage of its 5'-end with a dimethoxytrityl residue.
    Furukawa H; Momota K; Agatsuma T; Yamamoto I; Kimura S; Shimada K
    Antisense Nucleic Acid Drug Dev; 1997 Jun; 7(3):167-75. PubMed ID: 9212907
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CD4-independent infection of two CD4(-)/CCR5(-)/CXCR4(+) pre-T-cell lines by human and simian immunodeficiency viruses.
    Borsetti A; Parolin C; Ridolfi B; Sernicola L; Geraci A; Ensoli B; Titti F
    J Virol; 2000 Jul; 74(14):6689-94. PubMed ID: 10864687
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CD26 and HIV infection.
    Callebaut C; Hovanessian AG
    Res Virol; 1996; 147(1):67-9. PubMed ID: 8882342
    [No Abstract]   [Full Text] [Related]  

  • 38. Isochromophilones I and II, novel inhibitors against gp120-CD4 binding from Penicillium sp.
    Omura S; Tanaka H; Matsuzaki K; Ikeda H; Masuma R
    J Antibiot (Tokyo); 1993 Dec; 46(12):1908-11. PubMed ID: 8294253
    [No Abstract]   [Full Text] [Related]  

  • 39. CD4-binding regions of human immunodeficiency virus envelope glycoprotein gp120 defined by proteolytic digestion.
    Pollard SR; Meier W; Chow P; Rosa JJ; Wiley DC
    Proc Natl Acad Sci U S A; 1991 Dec; 88(24):11320-4. PubMed ID: 1763044
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CD4 masking during human immunodeficiency virus type 1 infection, quantified on peripheral blood lymphocytes, is a potential marker of disease progression.
    Carrière D; Vendrell J; Berthier A; Atoui N; Salhi SL; Reynes J; Gros P; Fontaine C; Jansen A; Huguet M; Ait-Cheik L; Pau B
    J Infect Dis; 1996 Mar; 173(3):565-73. PubMed ID: 8627018
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.